These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

815 related items for PubMed ID: 29336924

  • 1. Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
    Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L, Dolhain J, Gómez IP, Liese J, Knuf M.
    Vaccine; 2018 Feb 08; 36(7):986-996. PubMed ID: 29336924
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
    Arístegui J, Dal-Ré R, Díez-Delgado J, Marés J, Casanovas JM, García-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, Moraga F, Boceta R, García-Martínez JA.
    Vaccine; 2003 Sep 08; 21(25-26):3593-600. PubMed ID: 12922087
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety following primary and booster vaccination with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccine: a randomized trial in the United States.
    Klein NP, Abu-Elyazeed R, Cheuvart B, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2019 Sep 08; 15(4):809-821. PubMed ID: 30444673
    [Abstract] [Full Text] [Related]

  • 4. Safety profile of Infanrix hexa - 17 years of GSK's passive post-marketing surveillance.
    Puente Gómez I, Verheust C, Hanssens L, Dolhain J.
    Expert Rev Vaccines; 2020 Aug 08; 19(8):771-779. PubMed ID: 32729745
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1505-1515. PubMed ID: 28340322
    [Abstract] [Full Text] [Related]

  • 6. Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines.
    Dolhain J, Janssens W, Dindore V, Mihalyi A.
    Expert Rev Vaccines; 2020 May 03; 19(5):419-443. PubMed ID: 32419537
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and reactogenicity of two regimens of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio and Haemophilus influenzae type b vaccines administered to infants primed at birth with hepatitis B vaccine.
    Cheng HK, Rajadurai VS, Amin Z, Sriram B, Yee MF, Han HH, Bock HL, Safary A.
    Southeast Asian J Trop Med Public Health; 2004 Sep 03; 35(3):685-92. PubMed ID: 15689088
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F, Boisnard F, Thomas S, Sadorge C, Borrow R, PRI02C study group.
    Vaccine; 2017 Jun 27; 35(30):3764-3772. PubMed ID: 28583305
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants.
    Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM, Taiwan Infanrix-069 Study Group.
    J Formos Med Assoc; 2011 Jun 27; 110(6):415-22. PubMed ID: 21741011
    [Abstract] [Full Text] [Related]

  • 10. Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.
    Dolhain J, Janssens W, Sohn WY, Dindore V, Mukherjee P.
    Expert Rev Vaccines; 2019 Sep 27; 18(9):921-933. PubMed ID: 31328999
    [Abstract] [Full Text] [Related]

  • 11. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses.
    Heininger U, DTP-HBV-IPV-059 Study Group, DTP-HBV-IPV-096 Study Group, Sänger R, Jacquet JM, Schuerman L.
    Vaccine; 2007 Jan 22; 25(6):1055-63. PubMed ID: 17049692
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
    Dolhain J, Janssens W, Mesaros N, Hanssens L, Fierens F.
    Expert Rev Vaccines; 2018 Jun 22; 17(6):513-524. PubMed ID: 29920121
    [Abstract] [Full Text] [Related]

  • 17. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting.
    Lim FS, Phua KB, Lee BW, Quak SH, Teoh YL, Ramakrishnan G, Han HH, Van Der Meeren O, Jacquets JM, Bock HL.
    Southeast Asian J Trop Med Public Health; 2011 Jan 22; 42(1):138-47. PubMed ID: 21323176
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA, Assudani D, Kuriyakose S, Van Der Meeren O.
    Hum Vaccin Immunother; 2014 Jan 22; 10(10):2795-8. PubMed ID: 25483640
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.